{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T02:02:04Z","timestamp":1789524124898,"version":"build-2803163510"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T00:00:00Z","timestamp":1782518400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T00:00:00Z","timestamp":1789516800000},"content-version":"vor","delay-in-days":81,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"DOI":"10.1186\/s12885-026-16385-5","type":"journal-article","created":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T12:34:52Z","timestamp":1782563692000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Doxorubicin-loaded chitosan\/gold nanoparticles enhance anticancer effects and reduce CLMAT3 and ZNRD1-AS1 expression in colorectal cancer cells"],"prefix":"10.1186","volume":"26","author":[{"given":"Fatemeh","family":"Alizadeh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Rajabi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sina","family":"Goharmomayez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marziyeh","family":"Fathi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reza","family":"Safaralizadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,27]]},"reference":[{"key":"16385_CR1","doi-asserted-by":"crossref","unstructured":"Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. Cancer J Clin 2024, 74(1).","DOI":"10.3322\/caac.21820"},{"key":"16385_CR2","unstructured":"IARC adds data. from 12 countries in Asia to the CanScreen5 data repository, which now has screening data from more than 100 countries [ https:\/\/www.iarc.who.int\/cancer-type\/colorectal-cancer\/ ]."},{"issue":"12","key":"16385_CR3","doi-asserted-by":"publisher","first-page":"10082","DOI":"10.3390\/ijms241210082","volume":"24","author":"J Kim","year":"2023","unstructured":"Kim J, Cho H, Lim D-K, Joo MK, Kim K. Perspectives for improving the tumor targeting of nanomedicine via the EPR effect in clinical tumors. Int J Mol Sci. 2023;24(12):10082.","journal-title":"Int J Mol Sci"},{"key":"16385_CR4","doi-asserted-by":"publisher","first-page":"1612186","DOI":"10.3389\/pore.2025.1612186","volume":"31","author":"JM Ott","year":"2025","unstructured":"Ott JM, Gassenmaier V, Bitzer M, Sch\u00fcrch CM, Heitmann JS, Hagelstein I. B7-H3: a consistent marker in metastatic colorectal cancer with potential for targeted treatment. Pathol Oncol Res. 2025;31:1612186.","journal-title":"Pathol Oncol Res"},{"issue":"2","key":"16385_CR5","doi-asserted-by":"publisher","first-page":"107518","DOI":"10.1016\/j.cclet.2022.05.032","volume":"34","author":"R Liu","year":"2023","unstructured":"Liu R, Luo C, Pang Z, Zhang J, Ruan S, Wu M, Wang L, Sun T, Li N, Han L. Advances of nanoparticles as drug delivery systems for disease diagnosis and treatment. Chin Chem Lett. 2023;34(2):107518.","journal-title":"Chin Chem Lett"},{"issue":"3","key":"16385_CR6","doi-asserted-by":"publisher","first-page":"290","DOI":"10.3390\/pharmaceutics12030290","volume":"12","author":"Y Yin","year":"2020","unstructured":"Yin Y, Hu B, Yuan X, Cai L, Gao H, Yang Q. Nanogel: A versatile nano-delivery system for biomedical applications. Pharmaceutics. 2020;12(3):290.","journal-title":"Pharmaceutics"},{"issue":"2","key":"16385_CR7","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/j.drudis.2016.11.005","volume":"22","author":"M Cagel","year":"2017","unstructured":"Cagel M, Grotz E, Bernabeu E, Moretton MA, Chiappetta DA. Doxorubicin: nanotechnological overviews from bench to bedside. Drug Discovery Today. 2017;22(2):270\u201381.","journal-title":"Drug Discovery Today"},{"issue":"4","key":"16385_CR8","doi-asserted-by":"publisher","first-page":"659","DOI":"10.3390\/cells12040659","volume":"12","author":"M Kciuk","year":"2023","unstructured":"Kciuk M, Gieleci\u0144ska A, Mujwar S, Ko\u0142at D, Ka\u0142uzi\u0144ska-Ko\u0142at \u017b, Celik I, Kontek R. Doxorubicin\u2014an agent with multiple mechanisms of anticancer activity. Cells. 2023;12(4):659.","journal-title":"Cells"},{"issue":"5","key":"16385_CR9","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1007\/s11010-023-04783-3","volume":"479","author":"Y Robert Li","year":"2024","unstructured":"Robert Li Y, Traore K, Zhu H. Novel molecular mechanisms of doxorubicin cardiotoxicity: latest leading-edge advances and clinical implications. Mol Cell Biochem. 2024;479(5):1121\u201332.","journal-title":"Mol Cell Biochem"},{"issue":"9","key":"16385_CR10","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.3390\/ijms17091440","volume":"17","author":"PI Siafaka","year":"2016","unstructured":"Siafaka PI, \u00dcst\u00fcnda\u011f Okur N, Karavas E, Bikiaris DN. Surface modified multifunctional and stimuli responsive nanoparticles for drug targeting: current status and uses. Int J Mol Sci. 2016;17(9):1440.","journal-title":"Int J Mol Sci"},{"issue":"7","key":"16385_CR11","doi-asserted-by":"publisher","first-page":"1596","DOI":"10.3390\/polym15071596","volume":"15","author":"A Yusuf","year":"2023","unstructured":"Yusuf A, Almotairy ARZ, Henidi H, Alshehri OY, Aldughaim MS. Nanoparticles as drug delivery systems: a review of the implication of nanoparticles\u2019 physicochemical properties on responses in biological systems. Polymers. 2023;15(7):1596.","journal-title":"Polymers"},{"issue":"9","key":"16385_CR12","doi-asserted-by":"publisher","first-page":"2981","DOI":"10.3390\/molecules27092981","volume":"27","author":"K Wang","year":"2022","unstructured":"Wang K, Shen R, Meng T, Hu F, Yuan H. Nano-drug delivery systems based on different targeting mechanisms in the targeted therapy of colorectal cancer. Molecules. 2022;27(9):2981.","journal-title":"Molecules"},{"issue":"1","key":"16385_CR13","doi-asserted-by":"publisher","first-page":"165","DOI":"10.20517\/evcna.2025.161","volume":"7","author":"Q Li","year":"2026","unstructured":"Li Q, Ding Y, Shi Y, Qiu C, Lei L, Li S, Zhu Z, Zheng J, Qin C, Wang K. 80 years of extracellular vesicles: from discovery to clinical translation. Extracell Vesicles Circulating Nucleic Acids. 2026;7(1):165.","journal-title":"Extracell Vesicles Circulating Nucleic Acids"},{"issue":"1","key":"16385_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.5599\/admet.724","volume":"8","author":"R Rajput","year":"2020","unstructured":"Rajput R, Narkhede J, Naik J. Nanogels as nanocarriers for drug delivery: A review. Admet DMPK. 2020;8(1):1\u201315.","journal-title":"Admet DMPK"},{"key":"16385_CR15","doi-asserted-by":"publisher","first-page":"874510","DOI":"10.3389\/fphar.2022.874510","volume":"13","author":"AA Attama","year":"2022","unstructured":"Attama AA, Nnamani PO, Onokala OB, Ugwu AA, Onugwu AL. Nanogels as target drug delivery systems in cancer therapy: A review of the last decade. Front Pharmacol. 2022;13:874510.","journal-title":"Front Pharmacol"},{"key":"16385_CR16","doi-asserted-by":"crossref","unstructured":"Yang Y, Zheng X, Chen L, Gong X, Yang H, Duan X, Zhu Y. Multifunctional gold nanoparticles in cancer diagnosis and treatment. Int J Nanomed 2022:2041\u201367.","DOI":"10.2147\/IJN.S355142"},{"issue":"1","key":"16385_CR17","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1186\/s12943-023-01798-8","volume":"22","author":"P Kesharwani","year":"2023","unstructured":"Kesharwani P, Ma R, Sang L, Fatima M, Sheikh A, Abourehab MA, Gupta N, Chen Z-S, Zhou Y. Gold nanoparticles and gold nanorods in the landscape of cancer therapy. Mol Cancer. 2023;22(1):98.","journal-title":"Mol Cancer"},{"issue":"1","key":"16385_CR18","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1186\/s12943-025-02431-6","volume":"24","author":"L Zhuang","year":"2025","unstructured":"Zhuang L, Lian Y, Zhu T. Multifunctional gold nanoparticles: bridging detection, diagnosis, and targeted therapy in cancer. Mol Cancer. 2025;24(1):228.","journal-title":"Mol Cancer"},{"issue":"1","key":"16385_CR19","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1007\/s13237-020-00328-x","volume":"64","author":"A Bandyopadhyay","year":"2021","unstructured":"Bandyopadhyay A, Roy B, Shaw P, Mondal P, Mondal MK, Chowdhury P, Bhattacharya S, Chattopadhyay A. Chitosan-gold nanoparticles trigger apoptosis in human breast cancer cells in vitro. Nucleus. 2021;64(1):79\u201392.","journal-title":"Nucleus"},{"key":"16385_CR20","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.matchemphys.2018.12.089","volume":"226","author":"N Amanlou","year":"2019","unstructured":"Amanlou N, Parsa M, Rostamizadeh K, Sadighian S, Moghaddam F. Enhanced cytotoxic activity of curcumin on cancer cell lines by incorporating into gold\/chitosan nanogels. Mater Chem Phys. 2019;226:151\u20137.","journal-title":"Mater Chem Phys"},{"issue":"1","key":"16385_CR21","first-page":"4290705","volume":"2018","author":"H Katas","year":"2018","unstructured":"Katas H, Moden NZ, Lim CS, Celesistinus T, Chan JY, Ganasan P, Suleman Ismail Abdalla S. Biosynthesis and potential applications of silver and gold nanoparticles and their chitosan-based nanocomposites in nanomedicine. J Nanatechnol. 2018;2018(1):4290705.","journal-title":"J Nanatechnol"},{"key":"16385_CR22","doi-asserted-by":"crossref","unstructured":"Abu-Dief AM, Salaheldeen M, El-Dabea T. Recent advances in development of gold nanoparticles for drug delivery systems. J Mod Nanatechnol 2021, 1(1).","DOI":"10.53964\/jmn.2021001"},{"issue":"15","key":"16385_CR23","doi-asserted-by":"publisher","first-page":"5311","DOI":"10.3390\/ijms21155311","volume":"21","author":"OO Ogunwobi","year":"2020","unstructured":"Ogunwobi OO, Mahmood F, Akingboye A. Biomarkers in colorectal cancer: current research and future prospects. Int J Mol Sci. 2020;21(15):5311.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"16385_CR24","first-page":"2397863","volume":"2018","author":"G Pellino","year":"2018","unstructured":"Pellino G, Gallo G, Pallante P, Capasso R, De Stefano A, Maretto I, Malapelle U, Qiu S, Nikolaou S, Barina A. Noninvasive biomarkers of colorectal cancer: role in diagnosis and personalised treatment perspectives. Gastroenterol Res Pract. 2018;2018(1):2397863.","journal-title":"Gastroenterol Res Pract"},{"key":"16385_CR25","doi-asserted-by":"publisher","first-page":"153432","DOI":"10.1016\/j.prp.2021.153432","volume":"222","author":"S Ghafouri-Fard","year":"2021","unstructured":"Ghafouri-Fard S, Hussen BM, Gharebaghi A, Eghtedarian R, Taheri M. LncRNA signature in colorectal cancer. Pathology-Research Pract. 2021;222:153432.","journal-title":"Pathology-Research Pract"},{"issue":"D1","key":"16385_CR26","doi-asserted-by":"publisher","first-page":"D1295","DOI":"10.1093\/nar\/gkab1035","volume":"50","author":"M Yang","year":"2022","unstructured":"Yang M, Lu H, Liu J, Wu S, Kim P, Zhou X. lncRNAfunc: a knowledgebase of lncRNA function in human cancer. Nucleic Acids Res. 2022;50(D1):D1295\u2013306.","journal-title":"Nucleic Acids Res"},{"issue":"1","key":"16385_CR27","doi-asserted-by":"publisher","first-page":"197","DOI":"10.3390\/ijms18010197","volume":"18","author":"I M\u00e1rmol","year":"2017","unstructured":"M\u00e1rmol I, S\u00e1nchez-de-Diego C, Pradilla Dieste A, Cerrada E, Rodriguez Yoldi MJ. Colorectal carcinoma: a general overview and future perspectives in colorectal cancer. Int J Mol Sci. 2017;18(1):197.","journal-title":"Int J Mol Sci"},{"issue":"11","key":"16385_CR28","doi-asserted-by":"publisher","first-page":"8747","DOI":"10.1007\/s13277-015-3627-4","volume":"36","author":"L-c Ye","year":"2015","unstructured":"Ye L-c, Ren L, Qiu J-j, Zhu D-x, Chen T, Chang W-j, Lv S-x, Xu J. Aberrant expression of long noncoding RNAs in colorectal cancer with liver metastasis. Tumor biology. 2015;36(11):8747\u201354.","journal-title":"Tumor biology"},{"issue":"37","key":"16385_CR29","doi-asserted-by":"publisher","first-page":"58931","DOI":"10.18632\/oncotarget.10431","volume":"7","author":"L-c Ye","year":"2016","unstructured":"Ye L-c, Chen T, Zhu D-x, Lv S-x, Qiu J-j, Xu J, Yuan F-L, Wei Y. Downregulated long non-coding RNA CLMAT3 promotes the proliferation of colorectal cancer cells by targeting regulators of the cell cycle pathway. Oncotarget. 2016;7(37):58931.","journal-title":"Oncotarget"},{"key":"16385_CR30","unstructured":"Peng J-T, Li M-C. A functional Cis-eQTL locus in lncRNA ZNRD1-AS1 contributes to the susceptibility of endometrial cancer. Eur Rev Med Pharmacol Sci 2019, 23(18)."},{"issue":"11","key":"16385_CR31","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1002\/mc.22200","volume":"54","author":"J Wen","year":"2015","unstructured":"Wen J, Liu Y, Liu J, Liu L, Song C, Han J, Zhu L, Wang C, Chen J, Zhai X. Expression quantitative trait loci in long non-coding RNA ZNRD1\u2010AS1 influence both HBV infection and hepatocellular carcinoma development. Mol Carcinog. 2015;54(11):1275\u201382.","journal-title":"Mol Carcinog"},{"issue":"6","key":"16385_CR32","first-page":"5866","volume":"13","author":"G Yang","year":"2021","unstructured":"Yang G, Zeng C, Liu Y, Li D, Cui J. ZNRD1-AS1 knockdown alleviates malignant phenotype of retinoblastoma through miR-128-3p\/BMI1 axis. Am J Translational Res. 2021;13(6):5866.","journal-title":"Am J Translational Res"},{"issue":"1","key":"16385_CR33","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.carbpol.2013.02.034","volume":"95","author":"MA Kiechel","year":"2013","unstructured":"Kiechel MA, Schauer CL. Non-covalent crosslinkers for electrospun chitosan fibers. Carbohydr Polym. 2013;95(1):123\u201333.","journal-title":"Carbohydr Polym"},{"issue":"1\u20132","key":"16385_CR34","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.ijpharm.2015.05.032","volume":"490","author":"NS Elbialy","year":"2015","unstructured":"Elbialy NS, Fathy MM, Khalil WM. Doxorubicin loaded magnetic gold nanoparticles for in vivo targeted drug delivery. Int J Pharm. 2015;490(1\u20132):190\u20139.","journal-title":"Int J Pharm"},{"issue":"3","key":"16385_CR35","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Cancer J Clin. 2021;71(3):209\u201349.","journal-title":"Cancer J Clin"},{"issue":"1","key":"16385_CR36","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s13148-025-01844-w","volume":"17","author":"A Tahghighi","year":"2025","unstructured":"Tahghighi A, Seyedhashemi E, Mohammadi J, Moradi A, Esmaeili A, Pornour M, Jafarifar K, Ganji SM. Epigenetic marvels: exploring the landscape of colorectal cancer treatment through cutting-edge epigenetic-based drug strategies. Clin Epigenetics. 2025;17(1):34.","journal-title":"Clin Epigenetics"},{"issue":"1","key":"16385_CR37","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1186\/s13046-018-0896-y","volume":"37","author":"J Yu","year":"2018","unstructured":"Yu J, Han Z, Sun Z, Wang Y, Zheng M, Song C. LncRNA SLCO4A1-AS1 facilitates growth and metastasis of colorectal cancer through \u03b2-catenin-dependent Wnt pathway. J Experimental Clin Cancer Res. 2018;37(1):222.","journal-title":"J Experimental Clin Cancer Res"},{"key":"16385_CR38","doi-asserted-by":"crossref","unstructured":"Li C, Li W, Zhang Y, Zhang X, Liu T, Zhang Y, Yang Y, Wang L, Pan H, Ji J. Increased expression of antisense lncRNA SPINT1-AS1 predicts a poor prognosis in colorectal cancer and is negatively correlated with its sense transcript. OncoTargets therapy 2018:3969\u201378.","DOI":"10.2147\/OTT.S163883"},{"issue":"13","key":"16385_CR39","doi-asserted-by":"publisher","first-page":"17285","DOI":"10.18632\/aging.203209","volume":"13","author":"M-C Ba","year":"2021","unstructured":"Ba M-C, Ba Z, Gong Y-F, Lin K-P, Wu Y-B, Tu Y-N. Knockdown of lncRNA ZNRD1-AS1 suppresses gastric cancer cell proliferation and metastasis by targeting the miR-9-5p\/HSP90AA1 axis. Aging. 2021;13(13):17285.","journal-title":"Aging"},{"issue":"20","key":"16385_CR40","doi-asserted-by":"publisher","first-page":"7695","DOI":"10.1002\/cam4.3373","volume":"9","author":"Z Gao","year":"2020","unstructured":"Gao Z, Li S, Zhou X, Li H, He S. Knockdown of lncRNA ZNRD1-AS1 inhibits progression of bladder cancer by regulating miR\u2010194 and ZEB1. Cancer Med. 2020;9(20):7695\u2013705.","journal-title":"Cancer Med"},{"issue":"1","key":"16385_CR41","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1186\/s12943-022-01705-7","volume":"21","author":"J Wang","year":"2022","unstructured":"Wang J, Tan L, Yu X, Cao X, Jia B, Chen R, Li J. lncRNA ZNRD1-AS1 promotes malignant lung cell proliferation, migration, and angiogenesis via the miR-942\/TNS1 axis and is positively regulated by the m6A reader YTHDC2. Mol Cancer. 2022;21(1):229.","journal-title":"Mol Cancer"},{"issue":"1","key":"16385_CR42","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1186\/s11671-021-03628-6","volume":"16","author":"S Gavas","year":"2021","unstructured":"Gavas S, Quazi S, Karpi\u0144ski TM. Nanoparticles for cancer therapy: current progress and challenges. Nanoscale Res Lett. 2021;16(1):173.","journal-title":"Nanoscale Res Lett"},{"key":"16385_CR43","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.3389\/fphar.2018.01394","volume":"9","author":"B Fu","year":"2018","unstructured":"Fu B, Wang N, Tan H-Y, Li S, Cheung F, Feng Y. Multi-component herbal products in the prevention and treatment of chemotherapy-associated toxicity and side effects: a review on experimental and clinical evidences. Front Pharmacol. 2018;9:1394.","journal-title":"Front Pharmacol"},{"issue":"1","key":"16385_CR44","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1186\/s40164-025-00656-1","volume":"14","author":"J Venturini","year":"2025","unstructured":"Venturini J, Chakraborty A, Baysal MA, Tsimberidou AM. Developments in nanotechnology approaches for the treatment of solid tumors. Experimental Hematol Oncol. 2025;14(1):76.","journal-title":"Experimental Hematol Oncol"},{"issue":"1","key":"16385_CR45","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1186\/s12929-025-01161-7","volume":"32","author":"W Gonciarz","year":"2025","unstructured":"Gonciarz W, Balcerczak E, Brzezi\u0144ski M, Jele\u0144 A, Pietrzyk-Brzezi\u0144ska AJ, Narayanan VHB, Chmiela M. Chitosan-based formulations for therapeutic applications. A recent overview. J Biomed Sci. 2025;32(1):62.","journal-title":"J Biomed Sci"},{"issue":"5","key":"16385_CR46","doi-asserted-by":"publisher","first-page":"633","DOI":"10.3390\/pharmaceutics17050633","volume":"17","author":"V Gounden","year":"2025","unstructured":"Gounden V, Singh M. Gold Nanoparticle-Based Hydrogel: Application in Anticancer Drug Delivery and Wound Healing In Vitro. Pharmaceutics. 2025;17(5):633.","journal-title":"Pharmaceutics"},{"key":"16385_CR47","doi-asserted-by":"crossref","unstructured":"Wu X, Xin Y, Zhang H, Quan L, Ao Q. Biopolymer-based nanomedicine for cancer therapy: opportunities and challenges. Int J Nanomed 2024:7415\u201371.","DOI":"10.2147\/IJN.S460047"},{"issue":"18","key":"16385_CR48","doi-asserted-by":"publisher","first-page":"13402","DOI":"10.1039\/C4RA15356A","volume":"5","author":"S Borse","year":"2015","unstructured":"Borse S, Joshi S, Khan A. Enhanced in vitro cytotoxicity and cellular uptake of DNA bases functionalized gold nanoparticles in HeLa cell lines. RSC Adv. 2015;5(18):13402\u201310.","journal-title":"RSC Adv"},{"key":"16385_CR49","doi-asserted-by":"publisher","first-page":"113491","DOI":"10.1016\/j.colsurfb.2023.113491","volume":"230","author":"ID Souza","year":"2023","unstructured":"Souza ID, Saez V, Mansur CR. Lipid nanoparticles containing coenzyme Q10 for topical applications: An overview of their characterization. Colloids Surf B. 2023;230:113491.","journal-title":"Colloids Surf B"},{"issue":"11","key":"16385_CR50","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.3390\/metabo12111047","volume":"12","author":"R Ganesan","year":"2022","unstructured":"Ganesan R, Prabhakaran V-S, Valsala Gopalakrishnan A. Metabolomic signatures in doxorubicin-induced metabolites characterization, metabolic inhibition, and signaling pathway mechanisms in colon cancer HCT116 cells. Metabolites. 2022;12(11):1047.","journal-title":"Metabolites"},{"key":"16385_CR51","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.jconrel.2020.08.033","volume":"328","author":"M Mohammadi","year":"2020","unstructured":"Mohammadi M, Arabi L, Alibolandi M. Doxorubicin-loaded composite nanogels for cancer treatment. J Controlled Release. 2020;328:171\u201391.","journal-title":"J Controlled Release"},{"issue":"11","key":"16385_CR52","doi-asserted-by":"publisher","first-page":"2605","DOI":"10.1021\/acs.bioconjchem.6b00366","volume":"27","author":"NK Verma","year":"2016","unstructured":"Verma NK, Purohit MP, Equbal D, Dhiman N, Singh A, Kar AK, Shankar J, Tehlan S, Patnaik S. Targeted smart pH and thermoresponsive N, O-carboxymethyl chitosan conjugated nanogels for enhanced therapeutic efficacy of doxorubicin in MCF-7 breast cancer cells. Bioconjug Chem. 2016;27(11):2605\u201319.","journal-title":"Bioconjug Chem"},{"issue":"1","key":"16385_CR53","doi-asserted-by":"publisher","first-page":"21425","DOI":"10.1038\/s41598-021-00954-8","volume":"11","author":"A Rahmani","year":"2021","unstructured":"Rahmani A, Rahimi F, Iranshahi M, Kahroba H, Zarebkohan A, Talebi M, Salehi R, Mousavi HZ. Co-delivery of doxorubicin and conferone by novel pH-responsive \u03b2-cyclodextrin grafted micelles triggers apoptosis of metastatic human breast cancer cells. Sci Rep. 2021;11(1):21425.","journal-title":"Sci Rep"},{"issue":"1","key":"16385_CR54","doi-asserted-by":"publisher","first-page":"1606","DOI":"10.1038\/s41598-020-58527-0","volume":"10","author":"N Jalilzadeh","year":"2020","unstructured":"Jalilzadeh N, Samadi N, Salehi R, Dehghan G, Iranshahi M, Dadpour MR, Hamishehkar H. Novel nano-vehicle for delivery and efficiency of anticancer auraptene against colon cancer cells. Sci Rep. 2020;10(1):1606.","journal-title":"Sci Rep"},{"issue":"41","key":"16385_CR55","doi-asserted-by":"publisher","first-page":"34840","DOI":"10.1021\/acsami.8b12897","volume":"10","author":"Q Zhang","year":"2018","unstructured":"Zhang Q, Gong Y, Guo X-j, Zhang P, Ding C-f. Multifunctional gold nanoparticle-based fluorescence resonance energy-transfer probe for target drug delivery and cell fluorescence imaging. ACS Appl Mater Interfaces. 2018;10(41):34840\u20138.","journal-title":"ACS Appl Mater Interfaces"},{"issue":"11","key":"16385_CR56","first-page":"87","volume":"62","author":"M Seifi-Najmi","year":"2016","unstructured":"Seifi-Najmi M, Hajivalili M, Safaralizadeh R, Sadreddini S, Esmaeili S, Razavi R, Ahmadi M, Mikaeili H, Baradaran B, Shams-Asenjan K. SiRNA\/DOX lodeded chitosan based nanoparticles: Development, Characterization and in vitro evaluation on A549 lung cancer cell line. Cell Mol Biol. 2016;62(11):87\u201394.","journal-title":"Cell Mol Biol"},{"issue":"1","key":"16385_CR57","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/s12943-021-01488-3","volume":"21","author":"J Zuo","year":"2022","unstructured":"Zuo J, Zhang Z, Li M, Yang Y, Zheng B, Wang P, Huang C, Zhou S. The crosstalk between reactive oxygen species and noncoding RNAs: From cancer code to drug role. Mol Cancer. 2022;21(1):30.","journal-title":"Mol Cancer"},{"issue":"6","key":"16385_CR58","doi-asserted-by":"publisher","first-page":"883","DOI":"10.3390\/cancers11060883","volume":"11","author":"T Riedlinger","year":"2019","unstructured":"Riedlinger T, Bartkuhn M, Zimmermann T, Hake SB, Nist A, Stiewe T, Kracht M, Schmitz ML. Chemotherapeutic drugs inhibiting topoisomerase 1 activity impede cytokine-induced and NF-\u03baB p65-regulated gene expression. Cancers. 2019;11(6):883.","journal-title":"Cancers"},{"key":"16385_CR59","doi-asserted-by":"crossref","unstructured":"Gao J, Chen F, Hua M, Guo J, Nong Y, Tang Q, Zhong F, Qin L. Knockdown of lncRNA MIR31HG inhibits cell proliferation in human HaCaT keratinocytes. Biol Res 2018, 51.","DOI":"10.1186\/s40659-018-0181-8"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-026-16385-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-16385-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-16385-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T01:04:06Z","timestamp":1789520646000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12885-026-16385-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,27]]},"references-count":59,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["16385"],"URL":"https:\/\/doi.org\/10.1186\/s12885-026-16385-5","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,27]]},"assertion":[{"value":"11 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was approved by the Research Ethics Committee of Tabriz University (approval number IR.TABRIZU.REC.1403.113).","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"1100"}}